Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

May 21, 2024Open Access

Ver artículo completo

Extent of foetal exposure to maternal elexacaftor/tezacaftor/ivacaftor during pregnancy

DLDanni LiTianjin University of Traditional Chinese Medicine MDMartin DonnelleyUCL Australia DPDavid ParsonsSouth Australia Pathology

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Cystic fibrosis (CF) patients are living longer and healthier due to improved treatments, e.g. cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI), with treatment possibly occurring in pregnancy. The risk of ETI to foetuses remain unknown. Thus the effect of maternally administered ETI on foetal genetic and structural development was investigated.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Li et al. (Tue,) studied this question.

synapsesocial.com/papers/68e69105b6db643587617cbe https://doi.org/https://doi.org/10.1111/bph.16417

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A Th17- and Th2-skewed Cytokine Profile in Cystic Fibrosis Lungs Represents a Potential Risk Factor for <i>Pseudomonas aeruginosa</i> Infection2013 · 183 citations
2Pregnancy among cystic fibrosis women in the era of CFTR modulators2017 · 59 citations
3ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 20202020 · 1,152 citations
4FGF Signaling Expands Embryonic Cortical Surface Area by Regulating Notch-Dependent Neurogenesis2011 · 94 citations
5Development of the lung2017 · 673 citations

Grado de exposición fetal a elexacaftor/tezacaftor/ivacaftor materno durante el embarazo | Synapse